IONS vs the Top Picks average
| Pillar | IONS | Book avg | Diff |
|---|---|---|---|
| Quality | 0.11 | 0.83 | -0.72 |
| Growth | 0.26 | 0.92 | -0.66 |
| Value | 0.04 | 0.75 | -0.71 |
Averaged across the 30 names in today's Top Picks (mean score 82.4). A name can beat these averages and still be absent from the book — it also applies concentration limits.
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Ionis Pharmaceuticals, Inc. (IONS): score, valuation & FAQ
Ionis Pharmaceuticals, Inc. (IONS) is a Biotechnology company that scores 11.4 out of 100 on the Bull Rankings quality-growth model — a weak reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
The model flags PEG (D) and FCF (F) as weaker areas.
Is IONS a good stock to buy?
Bull Rankings scores IONS 11.4 out of 100 on its quality-growth model, which is a weak reading. A score is a quantitative screen of Ionis Pharmaceuticals, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does IONS score 11.4 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). IONS grades middle-of-pack across the strip, and is held back by PEG (D) and FCF (F). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is IONS overvalued or undervalued?
We don't compute a reliable discounted-cash-flow value for IONS — typically because it is not yet consistently profitable or free-cash-flow positive — so its valuation rests on growth and price-to-sales rather than on earnings-based intrinsic value. Judge it on the trajectory of the business, not a single multiple.
What are the main risks of investing in IONS?
D/E 4.98 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Free cash flow is negative (-$561m) — capital raises or debt issuance likely required; dilution / leverage risk. Revenue contracting -7% — the operational turn is not yet visible in the top line.
New to these metrics? The guides explain free cash flow, how the score works, and more in the learn hub — or run another name through the screener.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.